Developmental Activation of the Proteolipid Protein Promoter Transgene in Neuronal and Oligodendroglial Cells of Neostriatum in MiceFulton D.a, b · Paez P.a · Spreur V.a · Handley V.a · Colwell C.S.a · Campagnoni A.a · Fisher R.a
aDevelopmental and Molecular Neuroscience Group, Intellectual Development and Disabilities Research Center, Neuropsychiatric Institute, School of Medicine, The University of California at Los Angeles, Los Angeles, Calif., USA; bSchool of Life Sciences, The University of Warwick, Coventry, UK Corresponding Author
Prof. Robin Fisher
Room 301, Neuroscience Research Building
School of Medicine, The University of California at Los Angeles
635 Charles Young Drive South, Los Angeles, CA 90095 (USA)
Tel. +1 310 206 9360, E-Mail firstname.lastname@example.org
Prior studies suggest that non-canonical proteolipid protein (PLP) gene expression occurs during development in non-myelinating neurons as well as myelinating oligodendroglia in mammalian brain. To assess this possibility in neostriatum, a region of uncertain PLP gene expression in neurons, morphological and electrophysiological tools were used to determine phenotypes of cells with activation of a PLP promoter transgene during the early postnatal period in mice. PLP gene expression is evident in both neuronal and oligodendroglial phenotypes in developing neostriatum, a conclusion based on three novel observations: (1) An enhanced green fluorescent protein (EGFP) reporter of PLP promoter activation was localized in two distinct populations of cells, which exhibit collective, developmental differences of morphological and electrophysiological characteristics in accord with neuronal and oligodendroglial phenotypes of neostriatal cells found during the early postnatal period in both transgenic and wild-type mice. (2) The EGFP reporter of PLP promoter activation was appropriately positioned to serve as a regulator of PLP gene expression. It colocalized with native PLP proteins in both neuronal and oligodendroglial phenotypes; however, only soma-restricted PLP protein isoforms were found in the neuronal phenotype, while classic and soma-restricted PLP protein isoforms were found in the oligodendroglial phenotype. (3) As shown by EGFP reporter, PLP promoter activation was placed to regulate PLP gene expression in only one neuronal phenotype among the several that constitute neostriatum. It was localized in medium spiny neurons, but not large aspiny neurons. These outcomes have significant implications for the non-canonical functional roles of PLP gene expression in addition to myelinogenesis in mammalian brain, and are consistent with potentially independent pathologic loci in neurons during the course of human mutational disorders of PLP gene expression.
© 2011 S. Karger AG, Basel
Alternative splicing of the proteolipid protein (PLP) gene encodes two main ‘classic’ protein isoforms, PLP and DM20, constituents in myelin membrane of oligodendroglia that may have additional functions suggested by localization in neural precursors [1,2], myocardium, spermatozoa, and thymus [3,4,5,6,7]. In mice, alternative splicing of the cryptic 1.1 exon of the PLP gene also encodes two ‘soma-restricted’ protein isoforms, sr-PLP and sr-DM20, expressed by both neurons and oligodendroglia and associated with trafficking/recycling of endocytotic vesicles [8,9,10,11]. As shown by immunohistochemistry, neuronal expression of sr-isoforms (collectively termed sr-PLP) is complicated by distinct dense versus (vs.) sparse patterns of intracellular label accumulation in various neuronal populations and brain sites, particularly during early postnatal development . Despite substantial evidence for label specificity, sparsely labeled sr-PLP neurons are so numerous and widely distributed that their occurrence remains questionable, and they have received little experimental attention.
Mutant mice that localize enhanced green fluorescent protein (EGFP) reporter under control of activated PLP promoter transgenes now allow this problem to be addressed with alternative, intrinsically generated molecular probes that can lead and signify PLP gene expression with fewer technical difficulties than immunohistochemical detection of low levels of native proteins . In this report, we test the hypothesis that oligodendroglia, but not neurons, activate a PLP gene promoter (EGFP+ vs. EGFP– cells of respective lineage phenotypes) in neostriatum, a brain site that before and during myelinogenesis contains both densely labeled PLP and sr-PLP cells (possible oligodendroglia) and sparsely labeled sr-PLP cells (possible premyelinating stages of oligodendroglia and/or neurons) [pers. obs., ]. The investigated period is early postnatal development, when the label density distinction is established for sr-PLP cells. The outcome may be clinically relevant – duplicative mutations of human PLP1 gene in Pelizaeus-Merzbacher X-linked leukodystrophy (PMD) lead to progressive dysmyelination and neuronal degeneration in striatonigral components of basal ganglia [10,13,14]. Improved realization of the regional and cellular neuroanatomy of PLP gene expression may also contribute to uncovering the true range of its functional roles. For example, medullary neurons in myelin-deficient mutant rats accumulate abnormal PLP proteins, which disrupt potassium channels, alter rhythmic function of central pattern generators and yield lethal respiratory dysfunction [15,16].
Animal use protocols were approved by the UCLA Animal Research Committee consistent with guidelines of the National Institutes of Health. Acute experiments were performed on brain slices obtained from homozygous male and female transgenic mice (founder genotype, EGFP10 with high levels of reporter expression, shown by Southern blots, progeny genotype shown by positive generation of EGFP reporter in brain under control of a known PLP promoter sequence [see  for construct details]). Observations were obtained from 51 mice (4–16 days of postnatal age, P4–P16) in electrophysiological studies, 21 mice (P4–P20) in immunohistochemical studies, and materials from our anatomical collection. As detailed elsewhere , acute slices for electrophysiological recording were prepared from brains of mice anesthetized with isoflurane, decapitated and brains removed and placed rapidly in ice-cold, oxygenated slicing solution. Coronal slices (300 µm thickness) were cut by Vibratome, stored in oxygenated bicarbonate buffer recording solution (BBS) at 30°C for 30 min, then stored at room temperature (RT) before experiments.
Slicing solution contained (in mM): 26 NaHCO3, 1.25 NaH2PO4, 10 glucose, 125 NaCl, 3 KCl, 5 MgCl2, 1 CaCl2. BBS contained (in mM): 26 NaHCO3, 1.25 NaH2PO4, 10 glucose, 125 NaCl, 3 KCl, 2 MgCl2, 2 CaCl2. These solutions were bubbled with 95% 02/5% C02 at RT (20–23°C), with pH and osmolarity adjusted to 7.3 and 300–310 mM/kg, respectively. Voltage and current clamp recordings used a K+-based electrode solution that contained (in mM): 112.5 K-gluconate, 4 NaCl, 17.5 KCl, 0.5 CaCl2, 1 MgCl2, 0.5 Mg-ATP, 0.05 EGTA, 1 Na-HEPES, 0.1 tris-GTP, 0.1 leupeptin, 0.5 phosphocreatine (di-tris). The electrode solution also contained biocytin (0.05%), with pH and osmolarity adjusted to 7.2 and 290 mM/kg, respectively. Tetrodotoxin (Sigma-Aldrich, St. Louis, Mo., USA) stock solution was prepared in distilled water (1 mM), and diluted to a final concentration of 1–0.5 µM in BBS. 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, Sigma-Aldrich) stock solution was prepared in dimethyl sulfoxide (20 mM), and diluted to a final concentration of 20 µM in BBS. Both drugs were applied to slices via the perfusion system.
EGFP+ cells in neostriatum were identified by epifluorescent illumination for patch clamp recording, and GΩ seals were obtained under visual control by differential interference contrast illumination . Recording pipettes (3–6 MΩ) were made from glass capillary tubes (World Precision Instruments, Sarasota, Fla., USA) filled with K+-based electrode solution (junction potential = 12 mV, corrected off-line). Signals were amplified by an Axopatch 1D amplifier (Molecular Devices, Sunnyvale, Calif., USA), digitized at 10 kHz and filtered at 5 kHz. Signals were grounded with an AgCl bath electrode, and data acquisition was performed with pClamp version 9.0 (Molecular Devices). Cell membrane and recording parameters (capacitance, input resistance, access resistance, holding current, via pClamp) were monitored regularly during each experiment. In voltage clamp experiments, data were discarded if cells displayed access resistances ≥30 MΩ. Mean (+ standard error of the mean, X + SEM) access resistances for neostriatal neurons were: single action potential (AP) = 20.04 ± 1.31 MΩ and multiple AP = 20.88 ± 0.80 MΩ. Series resistance compensation was not applied, and leak and capacitance currents were subtracted digitally during voltage clamp using a P/N protocol. Na+ and K+ currents were activated from a holding potential of –82 mV with a series of depolarizing voltage commands (–82 to +58 mV, 10 mV steps with a duration of 150 ms). Spontaneous excitatory postsynaptic currents (sEPSCs) were recorded at holding potential of –82 mV in BBS, and analyzed off-line using Mini-Analysis (Synaptosoft Inc., Fort Lee, N.J., USA). Current-voltage (I-V) relationships, AP thresholds, kinetics and after-hyperpolarizations (AHPs) were determined for current clamp experiments by a pulse protocol series of depolarizing current steps (–0.1 to 0.2 nA, 0.1 nA steps, 150 ms duration).
For immunohistochemical preparations and analyses of patch-clamped cells, tissue was fixed by immersion in 4% paraformaldehyde, blocked and permeabilized in phosphate-buffered saline (PBS) containing 10% normal goat serum (NGS) and 0.2% Triton X100, and incubated overnight (4°C with agitation) in primary antibodies diluted in PBS with 10% NGS (carrier) . Slices were subsequently washed in PBS with 0.01% Triton X100, incubated in secondary antibody diluted in carrier (4–6 h, 1:800, RT with agitation), rinsed, and incubated in streptavidin-AMCA for detection of biocytin-filled cells (2 h, 1:400, RT with agitation; Vector Laboratories Inc., Burlingame, Calif., USA). Sections were air dried, mounted on glass slides and coverslipped with aqueous media (Aquamount, Lerner Laboratories, Pittsburgh, Pa., USA; EGFP was an intrinsic fluorescent label that could be visualized in aqueous media mounts on glass slides, with coverslips). The following primary antibodies were tested: mouse monoclonal anti-NeuN (1:800, Millipore, Billerica, Mass., USA); mouse monoclonal anti-MAP2 AP-20 clone (1:800, Sigma-Aldrich); rabbit monoclonal anti-DARPP-32 (1:400, Cell Signaling Technology, Boston, Mass., USA); rabbit polyconal anti-NG2 (1:300, Millipore), rat monoclonal anti-PDGFRα (1:200, BD Biosciences, San Jose, Calif., USA); rat anti-PLP/DM20 clone AA3 (gift from Steven Pfeiffer, University of Connecticut Health Science Center, Conn., USA); rabbit polyconal anti-srPLP (1:400). For sequential, multiple labeling studies, immunolabeling of primary antibodies was also produced by Alexa Fluor®-594 conjugated goat IgG antibodies raised against appropriate host species (Invitrogen, San Diego, Calif., USA). In all cases, specific labeling was abolished when these antibodies were deleted from primary incubation. Images were acquired with an inverted microscope (Olympus IX81) equipped with a spinning disc confocal setup.
Biocytin-filled cells were labeled, then characterized by photomicrography and camera lucida drawings . Digital photomicrographs of cells were derived from 35-mm color slide film (Nikon Inc., Melville, N.Y., USA).
For immunohistochemistry on perfusion-fixed tissue sections, mice were deeply anesthetized with sodium pentobarbital and perfused transcardially with ice-cold 4% paraformaldehyde. Brains were postfixed overnight, mounted in agarose, and sectioned in the coronal plane (50 µm thickness) by Vibratome. Methods for immunolabeling these sections were similar to those for thick slices with alterations in blocking/permeabilization solution (0.1% Triton X100 and 2% NGS), reduced duration of blocking step (2 h RT), and reduced duration of incubation in secondary antibody (1.5 h RT) .
Quantitative measurements of EGFP+ and immunoreactive cells were based on cell counts from confocal images acquired and displayed in SlideBook™ 4.0 software (Intelligent Imaging Innovations, Inc., Denver, Colo., USA). Three sections were analyzed for each condition, with counts obtained from six individual fields in each section. Positive cell counts were checked by examination of immunolabel and EGFP signal in multiple optical sections. Classic PLP expression was quantified using SlideBook™ 4.0 software. EGFP+ cells were selected in regions of interest, and software was used to measure average PLP signal intensity. Electrophysiological data were analyzed using Clampfit 8 (Molecular Devices). Prior to current measurement, traces were normalized to the average holding current from the period preceding the voltage step. Na+ currents were measured as peak inward response evoked during the first 10 ms of a depolarizing step to –22 mV. K+ currents were measured during the steady-state phase between 100 and 150 ms after onset of a depolarizing voltage command to +58 mV. AP slope and half-width were measured using pClamp, while AP and sEPSC frequencies were analyzed with Mini-Analysis. Normal distributions were tested in each data set using Kolmogorov-Smirnov tests. For data with normal distributions, single between-group comparisons were made by t tests, and multiple comparisons were investigated by one-way ANOVA followed by Bonferroni’s multiple comparison tests to detect pair-wise between-group differences. When normal distributions were absent, nonparametric Mann-Whitney U tests were used to make comparisons, and Kruskal-Wallis tests were used for multiple group comparisons, with between-group differences checked by Dunn’s multiple comparisons test. All statistical tests were computed with Prism 4.0 for Macintosh (Graphpad Software, Inc., El Camino Real, Calif., USA). A fixed value of pα < 0.05 for one-tailed tests was the criterion for reliable differences between groups. Cited values were Xs + SEMs unless otherwise noted.
EGFP+ cells with activated PLP promoter were widely distributed throughout immature forebrain throughout the period of development under investigation. At the beginning of this period (surveyed at low magnification for a P6 transgenic mouse in fig. 1), these cells were particularly prominent within neostriatum due to their close compaction and extensive distribution across the entire thickness of sections and slices. They had comparable arrangements and high cellular density throughout neostriatum. No consistent evidence of macroscopic ‘striasomal’ (i.e. cell island vs. matrix) compartmentation was seen in serial sections. At this early age, fiber fascicles of the internal capsule were clearly apparent in neostriatum, but contained few EGFP+ cells, consistent with their coincident low density of interfascicular oligodendroglia and paucity of myelin.
Neostriatal EGFP+ cells were categorized into three interspersed structural groups at this early postnatal stage: group I constituted the majority of EGFP+ cells, with spherical cell bodies and medium (sized) diameters >10 µm. Group II had bipolar (spindle-shaped) cell bodies and small diameters <10 (mostly 7–8) µm. Group III had spherical cell bodies and small diameters <10 (mostly 7–8) µm. Group I EGFP+ cells matched settled medium-sized neostriatal neurons in conventional histology and Golgi reports . Group II EGFP+ cells, which might have overlapped with group III due to neostriatal anisotrophy, matched neural progenitors (NPCs, most likely neuroblasts), migrating immature neurons and small oligodendroglial progenitor cells (OPCs) described in white matter tracts [12,17]. Group III, which became much more frequent with age, matched immature and mature interfascicular oligodendroglia described in white matter tracts . Structural groups extended the full depth of thick brain slices, and were not due to partial EGFP+ cell body profiles at slice faces.
Neostriatal EGFP+ cells were further delineated from P4–P16 by colocalization of cell lineage markers. NeuN, a pan-neuronal lineage marker, was located in frequent doubly labeled EGFP+/NeuN+ neostriatal cells in immunoreactive section faces (fig. 1). Comparable, but less densely aggregated, doubly labeled neurons were found in cerebral cortex, amygdala and hypothalamus. Among neostriatal NeuN+ neurons, 93% were also EGFP+, a finding cross-validated with the more mature neuronal lineage marker Map2. Approximately 76% of neostriatal Map2+ neurons were also EGFP+. Differences between proportions of doubly labeled neurons obtained with these two lineage markers might reflect different age-related schedules of accumulation of the targeted antigens, variations in their preservation, and/or distinct tissue penetrances of antibodies. Such neurons were not apparent in globus pallidus, although it contained substantial numbers of EGFP+ cells (fig. 1c). At P6, EGFP+/NeuN+ neurons were group I medium spherical cells (fig. 2a). PDGFRα and NG2, lineage markers of early and later developmental stages of OPCs, were also located in all brain sites containing EGFP+ cells [17,20,21]. At P6, EGFP+/PDGFRα+ and EGFP+/NG2 OPCs were small bipolar and spherical cells in groups II and III. EGFP+ cells in globus pallidus were akin to groups II and III (fig. 2b, c).
Allometric associations between form, size and lineage marker expression were evident for neostriatal EGFP+ cells during the P4–P16 study period. Form was quantified as minimum somatic diameter/maximum somatic diameter. Among EGFP+ cells, spherical form had values >0.5 and bipolar form had values <0.5. When categorized in this fashion, EGFP+/NeuN+ cells were reliably associated with spherical form of medium size, while EGFP+/ PDGFRα+ and EGFP+/NG2+ cells were reliably associated with bipolar and spherical forms of small size (fig. 2d). The proportion of small spherical cells that colocalized EGFP+/PDGFRα+ and EGFP+/NG2+ labels increased with OPC maturation, as shown by later-stage NG2 stage marker expression. The proportion of EGFP+/NeuN+ neurons in group I was reliably greater than proportions of EGFP+/PDGFRα+ and/or EGFP+/NG2+ EGFP+ OPCs in groups II and III, in accord with the expected stability of settled, postmitotic neurons unlike the extended mitotic passage of and subsequent maturation of OPCs (fig. 2e).
Neostriatal EGFP+ cells with activated PLP promoter transgene expressed distinct isoforms of native PLP proteins, as shown by immunohistochemistry.
At P5, prior to the onset of myelinogenesis, neither EGFP+ nor EGFP– cells localized classic PLP/DM20 isoforms (fig. 3a; detection of classic DM20, believed to show early expression, was uncertain in neostriatum with the employed monoclonal antibody directed against PLP; color plates for fig. 3, 4, 6, and 8 are shown in the online suppl. material; www.karger.com?doi=10.1159/000330321). EGFP label did not spread into processes in EGFP+ cells (0/30 examined cells). By and after P12, densely labeled EGFP+ cells (i.e. ‘bright’ fluorescence indicative of high cellular accumulations of the reporter) colocalized substantial PLP immunoreactivity (fig. 3b, c). Both EGFP and PLP labels spread into processes, which extended and branched up to 25 µm from origins (16/17 examined cells). Densely labeled EGFP+/PLP+ cells had small spherical characteristics of group III cells. They were putative immature and mature interfascicular oligodendroglia, as signified by their PLP signature and structural correspondence to these lineage stages. In association with myelination during and after the 4th week of postnatal development, label density in group III cells was so great that it obscured detection of group I and II cells. Distinction between sparsely and densely labeled EGFP+ cells was objectively measured by photometry, and found to be statistically reliable (fig. 3d). Unlike neostriatum, sparsely and densely labeled bipolar OPCs and more mature small spherical oligodendroglia in groups II and III were the only EGFP+ cells in globus pallidus.
Frequent, sparsely labeled group I (medium spherical) EGFP+ neostriatal neurons persisted throughout the study period. EGFP label did not spread into processes. In accord with a putative neuronal lineage, they did not express classic PLP (fig. 3b).
Both densely and sparsely labeled (groups I–III) neostriatal EGFP+ cells expressed sr-PLP/sr-DM20 isoforms (collectively termed sr-PLP cells; either or both sr isoforms might have been detected by the employed polyclonal sr-PLP antibodies). Regardless of intracellular accumulations of EGFP, EGFP+/sr-PLP+ cells were always found to be the most frequent cells in neostriatum from P4–P20 (fig. 4). The high degree of overlap between sparsely labeled EGFP+ cells and sr-PLP+ cells was stable across age, consistent with the persistent numerical predominance of sparsely labeled group I EGFP+ neostriatal neurons (contrast fig. 2d and 4d). This combination of double labeling, and consistently high frequencies of doubly labeled cells throughout early postnatal development, demonstrated that sparsely labeled group I EGFP+ neurons in neostriatum expressed sr-PLP in conjunction with activated PLP promoter.
The different structural characteristics of neostriatal cells with activated PLP promoter provided a valuable opportunity to target patch clamp recording studies for determination of viability and corresponding functional characteristics. We focused on sparsely labeled neostriatal EGFP+ cells, present from P4–P20 in transgenic mice, in order to compare the electrophysiological properties of nascent morphological groups.
During early postnatal development (P4–P7), the majority of sparsely labeled neostriatal EGFP+ cells exhibited high resistance membranes expected of immature cells, including neurons (3.10 ± 0.33 GΩ, n = 40), but their other functional characteristics displayed categorical differences. Three functional classes (termed for ease of distinction from the three structural groups) of neostriatal EGFP+ cells were recognized based on their excitability and expression of voltage-gated K+ currents (fig. 5a). Class I cells had moderate transient A-type (IKA) currents, sustained delayed rectifier K+ currents (IKDR), moderate-to-large Na+ currents (INa) and fired APs upon depolarization, which identified them as neurons . Class I was subdivided into neurons firing single APs versus multiple APs in response to positive current injection. Class II cells did not fire regenerative APs, lacked a prominent IKA, had a small IKDR, and possessed small INa. Class III cells did not fire APs, exhibited large IKA and sustained IKDR, and had small INa.
Electrophysiological properties of these functional classes are summarized in table 1. Consistent with the predominance of EGFP+/NeuN+ neurons, class I cells capable of firing APs formed the majority of the targeted sample (25 of 40 recorded cells). Among class I cells, AP waveforms were sharper in the multiple AP than the single AP subdivision, which reflected a range of maturational states (fig. 5b). For class I neurons in the multiple AP subdivision, AP slope was reliably increased while AP half-width was reliably reduced, indicative of enhanced AP kinetics (fig. 5b). AP rise and decay times were significantly reduced in these cells, while peak INa and IKDR were reliably increased (fig. 5c, d). Class II cells (8 of 40 recorded cells) had the low degree of excitability, apparent lack of IKA, and moderate IKDR typical of early NPCs or pre-settlement stages of development for neurons . Class II cells were distinguished from class III OPCs by absence of a pronounced IKA, which was reflected in a transient/steady-state IK ratio of ∼1. Class III cells (7 of 40 recorded cells) had the prominent IKA and IKDR, and lack of a regenerative AP typical of OPCs [17,24]. The large amplitude of IKA in putative OPCs increased the ratio of IKA/IKDR (transient/steady-state IK), not apparent in other classes of EGFP+ cells.
In all cases, class I cells were selected as representatives of medium spherical EGFP+ (structural group I) neostriatal cells. Double labeling revealed positive examples of class I cells that were EGFP+/Map2+ neurons, a cell lineage and developmental status consistent with their substantial Na+ current and regenerative APs (fig. 6c). Also in all cases, class II and III cells were selected as representatives of small bipolar EGFP+ (structural group II) neostriatal cells. Double labeling revealed no examples of class II EGFP+ neostriatal cells that expressed NG2, a negative outcome suggestive but not conclusive of their putative neuronal lineage (fig. 6b). These cells also escaped detection with neuronal lineage markers NeuN and Map2, probably due to their very early developmental status (fig. 2d); however, they regularly generated a graded low amplitude spike consistent with an early stage of neuronal differentiation (fig. 6b). Double labeling revealed positive examples of class III cells that were EGFP+/NG2+ OPCs (fig. 6a). In some cases, depolarization of putative OPCs produced a small spike whose amplitude increased in a graded fashion with increasing current injection (fig. 6a inset); nevertheless, kinetics, amplitude and lack of regenerative response distinguished these spikes from neuronal APs (fig. 6a, c).
The increasing excitability of neostriatal EGFP+ neurons during early postnatal development was due, at least in part, to progressive maturation of synaptic afferents and/or receptive substrates. The appearance of sEPSCs was contrasted between early and later postnatal periods in sparsely labeled EGFP+ neostriatal neurons identified by their morphological properties, pattern of membrane currents, and excitability (group I/class I; fig. 7). During the first postnatal week (P4–P5), few EGFP+ neurons had spontaneous membrane currents (2/14 recorded cells; fig. 7a), and when present, these currents had small amplitudes (∼5pA). During the second postnatal week (P9–P15), most EGFP+ neurons had numerous spontaneous currents (12/14 recorded cells; fig. 7a), and these currents had increased amplitudes (range = 5–50 pA). In these more mature neurons, current frequency was attenuated by the AMPA-type glutamate receptor antagonist CNQX (pre-CNQX: 13 ± 3 Hz, n = 3; post-CNQX: 2 ± 2 Hz, n = 3), and thus represented glutamatergic sEPSCs. The average frequency of sEPCSs increased between the first and second postnatal weeks (fig. 7b). EGFP+ neurons also had a reliable decrease in input resistance during this period (fig. 7c inset), while input resistance was always negatively correlated with sEPSC frequency (fig. 7c). Progressive, parallel decreases in input resistance and increases in synaptic input were consistent with dendritic growth and/or spine generation.
The collective structural and functional characteristics of EGFP+ neostriatal neurons with activated PLP promoter identified them as medium spiny neurons. Medium spiny cells (with two minor variants that both emit projection and local axonal collaterals) constitute approximately 95% of neostriatal neurons [18,25], a value that closely approximated the prevalence of EGFP+/NeuN+ neostriatal neurons observed during and after the first postnatal week in transgenic mice. Between P4–P20, frequent medium EGFP+ neurons and infrequent large EGFP– cells, likely in the latter case to have represented large ‘aspiny’ neurons that usually emit only local axons, were found in neostriatum. This observation indicated that PLP promoter activation was widespread but restricted to particular type(s) of neostriatal neurons. This categorization also afforded a valuable opportunity to target patch clamp recordings to these two contrasting types of cells for comparisons of their development in the early postnatal period.
Medium spherical EGFP+ neostriatal neurons (group I/class I) displayed a striking electrophysiological uniformity. They showed little or no spontaneous AP generation at normal resting potentials (fig. 8a) and significant spike accommodation during current injection (fig. 8b). Their mean input resistance (642 ± 0.09 MΩ) was comparable to values obtained previously for immature medium spiny neurons [26,27] and was significantly greater than the value obtained from large EGFP– cells (380 ± 1.49 MΩ; U = 11.5, p < 0.05). Similar to an earlier report , EGFP+ neurons had a pronounced inward rectification of the I-V relationship during hyperpolarizing and depolarizing current injection, responses that were absent in large EGFP– cells (fig. 8c). EGFP+ neurons also had a positive expression of DARPP-32, a dopamine receptor-associated protein sometimes used to identify putative medium spiny neurons in intact forebrain (fig. 8d) . When recovered after intracellular biocytin injections, all EGFP+ neurons had medium-sized and spherical cell bodies of 10- to 15-µm diameter (fig. 9a). Their dendrites (4–7 primary dendrites/neuron) had thin shafts and numerous varicosities, which decreased with age. Their distal dendritic segments, usually >3rd branch order, emitted characteristic spines, which became more frequent and uniformly shaped with age (fig. 9). Thus, sparsely labeled EGFP+ neurons were directly identified as developing medium spiny neostriatal neurons consistent with previous functional and structural descriptions obtained from young rats [26,27].
Large EGFP– cells were also neurons, as shown by spontaneous generation of APs at normal resting potentials (fig. 8a). In contrast to EGFP+ neurons, they did not exhibit spike accommodation during current injection (fig. 8b). Their post-AP AHPs were reliably prolonged when compared to EGFP+ neurons (21.6 ± 3.89 vs. 2.48 ± 0.54 ms). These properties resembled those found for aspiny neurons of comparable size in young rats . There was also evidence of additional diversity among EGFP– neurons, with one example (1/20 cells) of a fast-spiking cell with a high firing frequency (114.3 Hz) and brief AP/AHP kinetics . When recovered after intracellular biocytin injections, all EGFP– neurons had large-sized multipolar cell bodies of 20- to 30-µm maximum diameter, and were reliably bigger than EGFP+ neurons obtained at the same age. Their proximal dendritic segments tended to be thick, dendritic varicosities were uncommon, and dendritic spines were rarely observed regardless of age.
Novel evidence obtained in this investigation demonstrates beyond a reasonable doubt that PLP gene expression occurs in both neuronal and oligodendroglial phenotypes in the developing neostriatum of mice that bear the PLP promoter transgene. This conclusion is based on three fundamental observations. First, an EGFP reporter of PLP promoter activation in transgenic mice is certainly localized in two distinct populations of cells, which exhibit collective, emergent differences of morphological and physiological characteristics in accord with the neuronal and oligodendroglial phenotypes of neostriatal cells found during early postnatal development in both mutant and wild-type mice [17,24,31,32]. The present assessment of characteristics that comprise the phenotypes is not exhaustive, but it is sufficient to demonstrate the age-related divergence of viable neuronal and oligodendroglial cells that activate the PLP promoter transgene, and to resolve, particularly by electrophysiological means, several key morphological characteristics shared by these two phenotypes during their early, primitive stages of development. Second, the EGFP reporter of PLP promoter activation in transgenic mice is appropriately positioned to serve as a regulator of PLP gene expression. It is colocalized with native PLP proteins in both neuronal and oligodendroglial phenotypes; however, only soma-restricted(sr) PLP protein isoforms are localized in the neuronal phenotype, while classic and sr-PLP isoforms are localized in the oligodendroglial phenotype [8,10]. Third, the EGFP reporter of PLP promoter activation in transgenic mice is placed to regulate PLP gene expression in only one neuronal phenotype among the several that constitute neostriatum. It is localized in medium spiny neurons, but not large aspiny neurons [26,27]. Taken singly or together, these positive results necessarily lead to rejection of the hypothesis that oligodendroglia, but not neurons, exhibit PLP gene promoter activation in neostriatum of mice that bear the PLP promoter transgene.
The new observations are a modest, incremental advance in the elucidation of PLP gene expression in the oligodendroglial phenotype. As expected, morphological and electrophysiological patterns of development for the oligodendroglial phenotype in fiber fascicles of internal capsule that pass through neostriatum closely resemble patterns obtained in corpus callosum and subcortical white matter . The former is rarely studied, while the latter is the subject of many prior investigations. Of greater significance, immature and mature oligodendroglia in transgenic and wild-type mice contain the molecular machinery required for the production of PLP proteins, as indicated by colocalizations of interrelated mRNA, promoter and proteins [10,33,34,35]. With age, the oligodendroglial phenotype shifts from a sparse to a dense pattern of intracellular EGFP+ labeling, an upregulation likely to reflect a high level of activation (and consequent reporter accumulation) of native and transgene PLP promoter elements triggered only within the oligodendroglial phenotype by events within the context of normal development. This shift coincides with previously described up-regulations of PLP mRNA and classic PLP levels that accompany myelinogenesis. The sparse pattern of intracellular EGFP+ label precedes the shift, and may reflect a low, steady-state activation of native and transgene promoter elements that accompanies expression of sr-PLP, but not classic PLP, during early development (OPCs) and throughout myelinogenesis (immature and mature interfascicular oligodendroglia) [10,12].
The new observations are a significant advance in the elucidation of PLP gene expression in the neuronal phenotype. Due to technical limitations, previous in situ hybridization and immunohistochemical studies do not recount localization of substantial levels of mRNA or protein markers of PLP gene expression in neostriatal neurons in wild-type mice. However, the development of the neostriatal neuronal phenotype with PLP promoter transgene activation resembles, and likely precedes, the sparse label pattern observed in the oligodendroglial phenotype. This pattern of sparse EGFP+ label is maintained throughout early postnatal development and the establishment of synaptic connectivity. It may reflect a low, steady-state activation of native and transgene promoter elements that accompanies expression of sr-PLP, but not classic PLP. It is not upregulated during myelinogenesis, which is not an autonomous function of the neuronal phenotype. To a reasonable certainty, colocalization of EGFP and sr-PLP in neostriatal neurons of transgenic mice is in accord with marginal observations of sparsely labeled neostriatal neurons that localize sr-PLP in wild-type mice [pers. obs., ]. Taken together, these results suggest that PLP gene expression, insofar as it pertains to production of sr-PLP, is a shared characteristic of neuronal and oligodendroglial phenotypes in neostriatum in mice, perhaps derived from a common precursor within their respective cell lineages.
PLP promoter transgene activation in a neuronal phenotype in neostriatum is consistent with and extends previous reports of EGFP reporter localization in brainstem and hypothalamic neurons [2,11]. These earlier studies, which do recognize the colocalization relationship between PLP promoter transgene and sr-PLP expression in neuronal and oligodendroglial phenotypes, do not localize these markers in neostriatum. They provide no systematic account of emergent morphological and electrophysiological characteristics of neurons with PLP promoter transgene activation as they progress through distinct developmental stages, important features of the present study. A recent report demonstrates conditional activation of a PLP promoter transgene in forebrain neurons . Focused on cerebral cortex, it also shows derivation of activated neostriatal neurons from a pre-existent neuronal lineage, similar to our findings of immature EGFP+ NPCs and neurons, and consistent with infrequent but persistent postnatal neurogenesis of mouse neostriatum. In neostriatal neurons, tamoxifen triggered, over a permissive background of native development, a late, rapid onset of low, steady-state transgene activation accompanied by accumulation of PLP mRNA. We show that the native course of development is adequate to trigger and maintain an early, gradual onset of low, steady-state transgene activation in neostriatal neurons.
There is probable cause to suspect that PLP promoter transgene activation leads to upregulation of PLP proteins in mutant vs. wild-type mice, an issue complicated by inclusion of lineage-specific enhancers in constructs used to generate these transgenes . In young neostriatal neurons, sr-PLP is clearly shown in transgenic mice by fluorescence immunohistochemistry, but less certainly shown in wild-type mice by peroxidase immunohistochemistry, a more efficient detection method. Enhanced levels of PLP gene expression in transgenic mice do not appear to impair the viability of neuronal or oligodendroglial phenotypes, which resemble intact neostriatum in wild-type rodents studied at similar ages [26,27,29]. Such negative functional outcomes, drawn from indirect comparisons of transgenic and wild-type mice, are suggestive but not conclusive; however, they weigh against proposals that augmented levels of PLP gene products, particularly classic PLP isoforms, reduce cell survival via programmed cell death [6,8].
The new evidence for PLP promoter transgene activation and sr-PLP expression in a single neuronal phenotype in developing neostriatum, medium spiny neurons, has several significant implications: (1) It lends credibility to recognition of sparse sr-PLP accumulation in this largest subpopulation of mature neostriatal neurons, which indicates that PLP gene expression has both maintenance and developmental roles in restricted neuronal phenotypes. Within neostriatum, contrasts between medium spiny neurons (with sr-PLP expression) and large aspiny neurons (without sr-PLP expression) may help to resolve non-canonical roles of PLP isoforms in endocytotic trafficking/recycling, ion exchange, and/or process outgrowth . (2) Medium spiny neostriatal neurons synthesize γ-aminobutyric acid as their signature inhibitory neurotransmitter , a characteristic not associated with neocortical, brainstem and hypothalamic neurons previously shown to have PLP gene expression [10,11,15,30]. This suggests that PLP gene expression is unrestricted in regard to excitatory vs. inhibitory neurotransmitter signatures. (3) Medium spiny neostriatal neurons emit myelinated projection and unmyelinated local collateral axons [38,39]. Myelination of projection axons through interactions with interfascicular oligodendroglia is unlikely to be a direct consequence of their autonomous PLP gene expression, initiated before the onset of myelinogenesis and with different outcomes in projection vs. local axonal domains.
The sr-PLP products of the PLP gene arise from alternative splicing of mouse exon 1.1 . This exon is not conserved in humans, but two novel exons found within intron 1 of the human PLP1 gene  may have similar functions to those performed by the mouse sr-PLP transcript. Their alternative splicing generates four novel mRNAs. Three show neuronal expression in human cerebral cortex, cerebellum and neostriatum, and one leads to a neuronal PLP protein product. These human PLP transcripts and proteins show patterns of expression that resemble mouse sr-PLP [10,11], and neostriatal expression of PLP gene products may be a conserved feature of mammalian evolution. Neurons may also serve as a pathologic locus, and perhaps a primary pathologic cause, in human neurological disorders associated with mutations in the PLP gene [15,16]. Accordingly, postmortem tissue shows significant neuronal loss in PMD cases with duplications of human PLP1. Many sites of neuronal loss in this disorder correspond to brain regions in transgenic mice, including neostriatum, that contain neuronal phenotypes capable of PLP promoter activation and sr-PLP expression . Similar forms of degeneration of neostriatal projection neurons occur in spastic paraplegia type 2  in association with mutations in the human PLP1 gene.
This work was supported by National Multiple Sclerosis Society pilot grant No. PP1562 (A.C.), NINDS grant RO1NS023022–23 (A.C.), and a Stein/Oppenheimer Endowment Award (D.F. and A.C.). We thank Dr. Cristina Ghiani, Donna Crandall and Dr. Ellen Carpenter for assistance.
Prof. Robin Fisher
Room 301, Neuroscience Research Building
School of Medicine, The University of California at Los Angeles
635 Charles Young Drive South, Los Angeles, CA 90095 (USA)
Tel. +1 310 206 9360, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.